Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Brodalumab 1.5 mL vs 1.0 mL + 0.5 mL Syringes
NCT02173392Phase 1Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Sep 2014
- Primary completion
- Nov 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of brodalumab in psoriasis (2 arms), sponsored by Valeant Pharmaceuticals. Primary endpoints: Maximum Observed Concentration at 60 days and Area Under the Curve at 60 days. Started Sep 2014; status: completed.
02
Drugs
brodalumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT02173392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02173392.